Autolus Therapeutics plc
NASDAQ:AUTLBiotechnology
+$0.01 today
- Market cap
- $282.13M
- Beta
- 2.01
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$1.09
Volume 2.56M
Average 1.60M
AUTL Short-term Investments
Marketable securities and deposits the company expects to convert to cash within a year.
Autolus Therapeutics plcNASDAQ: AUTL
Short-term Investments · Q1 FY2026 · quarter ended Mar 2026
Short-term investments falls 76.6% from a year ago
Short-term investments stood at $98.51M at the end of Q1 FY2026, down 76.6% from a year earlier and down 49.9% from the prior quarter.
Context
- Short-term investments amounted to 18.7% of total assets at the end of Q1 FY2026, down 37.7 pp from a year earlier.
- Short-term investments increased in 1 of the last 3 fiscal years.
What to watch
Whether short-term investments keeps falling in the next quarterly balance sheet after a -76.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 196.58M USD
- Year-over-year change
- -45.5%
| Period | Period end | Short-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 196.58M | -45.5% |
| FY2024 | 2024-12-31 | 360.64M | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Short-term Investments vs competitors
How AUTL compares with its peers on the latest reported figures
- AUTL's Mar 2026 short-term investments of $98.51M is the 7th highest of the 10 companies compared; the peer median is $135.25M.
- Its year-over-year change of -76.6% is the lowest of 8, against a peer median of -26.0%.
- Short-term investments amounts to 18.7% of total assets for AUTL, versus a peer median of 46.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $391.8M | -45.1% | -42.0% | 23.3% | |
| Mar 2026 | $236.58M | -0.4% | -24.2% | 59.7% | |
| Mar 2026 | $163.25M | -9.7% | -28.7% | 46.6% | |
| Mar 2026 | $150.66M | +32.1% | +163.8% | 52.1% | |
| Mar 2026 | $135.25M | -30.8% | -25.2% | 47.5% | |
| Mar 2026 | $105.57M | -41.0% | -12.5% | 70.9% | |
| Mar 2026 | $98.51M | -76.6% | — | 18.7% | |
| Mar 2026 | $83.76M | -26.0% | -37.9% | 25.6% | |
| Mar 2026 | $1.81M | — | — | 1.3% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding AUTL) | $135.25M | -26.0% | -25.2% | 46.6% | |
Competitors are the stored peer set for AUTL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 310.34M | 382.44M | 239.57M | 227.38M | 104.13M |
| Short-term Investments | 0 | 0 | 0 | 360.64M | 196.58M |
| Net Receivables | 68K | 28.98M | 1.05M | 48.24M | 75.79M |
| Inventory | 0 | 0 | 0 | 4.14M | 33.21M |
| Other Current Assets | 27.83M | 2.02M | 26.05M | 5.32M | 4.93M |
| Total Current Assets | 346.95M | 425.77M | 275.3M | 660.93M | 435.92M |
| Property, Plant & Equipment (Net) | 52.32M | 58.42M | 95.65M | 105.05M | 128.5M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 65K | 0 | 0 | 12.37M | 19.81M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 2.08M | 3.06M | 3.24M | 3.56M |
| Other Non-current Assets | 6.23M | 4.01M | 1.36M | 1.13M | 1.28M |
| Total Non-current Assets | 58.61M | 64.5M | 100.08M | 121.8M | 153.15M |
| Total Assets | 405.56M | 490.27M | 375.38M | 782.73M | 589.07M |
| Account Payables | 431K | 531K | 103K | 1.97M | 3.08M |
| Short-term Debt | 0 | 0 | 0 | 0 | 14.57M |
| Tax Payables | 0 | 0 | 0 | 3.59M | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 160K | 10.57M | 15.29M | 23.66M | 55.79M |
| Total Current Liabilities | 28.55M | 46.37M | 44.74M | 60.74M | 73.44M |
| Long-term Debt | 47.02M | 0 | 0 | 0 | 270.2M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 128K | 126.02M | 171.26M | 245.03M | 477K |
| Total Non-current Liabilities | 63.69M | 145.23M | 219.17M | 294.66M | 337.5M |
| Total Liabilities | 92.24M | 191.6M | 263.91M | 355.4M | 410.94M |
| Common Stock | 4K | 8K | 8K | 12K | 12K |
| Retained Earnings | (521.34M) | (670.18M) | (878.56M) | (1.1B) | (1.39B) |
| Accumulated OCI | (8.45M) | (38.9M) | (28.99M) | (29.17M) | (5.36M) |
| Other Stockholders Equity | (1) | 118K | 118K | 118K | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 313.32M | 298.67M | 111.47M | 427.33M | 178.13M |
| Total Debt | 68.01M | 24.26M | 52.97M | 52.63M | 351.59M |
| Net Debt | (242.32M) | (358.18M) | (186.6M) | (174.75M) | 247.45M |
Autolus Therapeutics plc
NASDAQ:AUTL
Intrinsic Alpha fair value
Locked
Current Price
$1.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.